CLOs on the Move


 
Our platforms use silicon nanopore chips and proprietary biochemistry to accurately detect and differentiate single molecules. We will help transform point-of-care testing and third generation sequencing.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.ontera.bio
  • 2155 Delaware Avenue Suite 225
    Santa Cruz, CA USA 95060
  • Phone: n/a

Executives

Name Title Contact Details

Similar Companies

Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines.

Tetra Bio-Pharma

Tetra Bio-Pharma is a multi subsidiary publicly traded company engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Aerin Medical

Aerin`s advanced treatment platform utilizes low-power radiofrequency energy to remodel nasal soft tissues and address the underlying cause of nasal congestion. Treatment styluses are uniquely designed for each procedure and deliver energy to the target tissue surface without the need for incisions or tissue penetration.Proprietary algorithms ensure that targeted tissues are exposed to carefully controlled energy resulting in treatment temperatures that are below the tissue ablation range. The technology is protected by a comprehensive patent estate consisting of both method and design patents.

Apogee Therapeutics

Apogee Therapeutics is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology indications with high unmet need. Apogee`s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company`s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today`s standard of care.

DMC

DMC is leading the low cost sustainable transformation of multiple product markets.